MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
common stock equity,...
$13,628,070
Proceeds from issuance of
common stock upon...
$3,467,695
Net cash provided by
financing activities
$17,085,488
Canceled cashflow
$10,277
Net change in cash,
cash equivalents
$2,908,292
Canceled cashflow
$14,177,196
Issuance costs of stock
dividend
$10,277
Amortization of right-of-use
assets
$406,992
Depreciation
$291,908
Advances, deposits, and
other current assets
-$193,507
Stock-based compensation
$127,374
Fair value of shares
issued in exchange for...
$99,040
Non-cash effect of
reverse stock split
$704
Net cash used in
operating activities
-$13,896,624
Net cash (used in)
provided by investing...
-$280,572
Canceled cashflow
$1,119,525
Net loss
-$14,495,028
Purchases of property and
equipment
$280,572
Accounts payable and
accrued liabilities
-$521,121
Back
Back
Cash Flow
source: myfinsight.com
Imunon, Inc. (IMNN)
Imunon, Inc. (IMNN)